Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects

Intensive Care Medicine

Volumn 34, Issue 4, 2008, Pages 755-762

  Ehrmann, Stephan ^a   Mercier, Emmanuelle ^a   Vecellio, Laurent ^b   Ternant, David ^a   Paintaud, Gilles ^a   Dequin, Pierre François ^a  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

Administration, aerosol; Drug evaluation; Respiration, artificial

Indexed keywords

AMIKACIN;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; BODY WEIGHT; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDICAL NEBULIZER; NEBULIZATION; NORMAL HUMAN; PRESSURE SUPPORT VENTILATION;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; AMIKACIN; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE;

EID: 43349095491     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-007-0935-1     Document Type: Article

References (30)

1. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C (1999) The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 159:1249-1256
2. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, Kollef MH (2002) Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 122:2115-2121
3. Anonymous (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388-416
4. Rello J, Paiva JA, Baraibar J, Barcenilla F, Bodi M, Castander D, Correa H, Diaz E, Garnacho J, Llorio M, Rios M, Rodriguez A, Sole-Violan J (2001) International Conference for the Development of Consensus on the Diagnosis and Treatment of Ventilator-associated Pneumonia. Chest 120:955-970
5. Panidis D, Markantonis SL, Boutzouka E, Karatzas S, Baltopoulos G (2005) Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 128:545-552
6. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S (2003) Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290:2588-2598
7. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 340:23-30
8. Moss RB (2002) Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 121:55-63
9. Mukhopadhyay S, Singh M, Cater JI, Ogston S, Franklin M, Olver RE (1996) Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax 51:364-368
10. Palmer LB, Smaldone GC, Simon SR, O'Riordan TG, Cuccia A (1998) Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 26:31-39
11. Elman M, Goldstein I, Marquette CH, Wallet F, Lenaour G, Rouby JJ (2002) Influence of lung aeration on pulmonary concentrations of nebulized and intravenous amikacin in ventilated piglets with severe bronchopneumonia. Anesthesiology 97:199-206
12. Ferrari F, Goldstein I, Nieszkowszka A, Elman M, Marquette CH, Rouby JJ (2003) Lack of lung tissue and systemic accumulation after consecutive daily aerosols of amikacin in ventilated piglets with healthy lungs. Anesthesiology 98:1016-1019
13. Goldstein I, Wallet F, Nicolas-Robin A, Ferrari F, Marquette CH, Rouby JJ (2002) Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am J Respir Crit Care Med 166:1375-1381
14. Goldstein I, Wallet F, Robert J, Becquemin MH, Marquette CH, Rouby JJ (2002) Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am J Respir Crit Care Med 165:171-175
15. O'Doherty MJ, Thomas SH, Page CJ, Treacher DF, Nunan TO (1992) Delivery of a nebulized aerosol to a lung model during mechanical ventilation. Effect of ventilator settings and nebulizer type, position, and volume of fill. Am Rev Respir Dis 146:383-388
16. Vecellio L, Guerin C, Grimbert D, De Monte M, Diot P (2005) In vitro study and semiempirical model for aerosol delivery control during mechanical ventilation. Intensive Care Med 31:871-876
17. Miller DD, Amin MM, Palmer LB, Shah AR, Smaldone GC (2003) Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med 168:1205-1209
18. E Mercier, S Ehrmann, L Vecellio, D Ternant, PF Dequin (2006) High dose of nebulized amikacin during non invasive positive pressure ventilation (NPPV) in healthy volunteers (HV): pharmacokinetic and tolerance. American Thoracic Society International Conference 2006, San Diego. Am J Respir Crit Care Med 173:A150
19. Dennis JH, Stenton SC, Beach JR, Avery AJ, Walters EH, Hendrick DJ (1990) Jet and ultrasonic nebuliser output: use of a new method for direct measurement of aerosol output. Thorax 45:728-732
20. Gibaldi M, D Perrier (1982) Noncompartmental analysis based on statistical moment theory. In: Pharmacokinetics. Dekker, Basel, pp 409-417
21. Lanao JM, Vicente MT, Sayalero ML, Dominguez-Gil A (1992) A computer program (DCN) for numerical convolution and deconvolution of pharmacokinetic functions. J Pharmacobiodyn 15:203-214
22. Beaubien AR, Desjardins S, Ormsby E, Bayne A, Carrier K, Cauchy MJ, Henri R, Hodgen M, Salley J, St Pierre A (1989) Incidence of amikacin ototoxicity: a sigmoid function of total drug exposure independent of plasma levels. Am J Otolaryngol 10:234-243
23. Begg EJ, Barclay ML, Duffull SB (1995) A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 39:605-609
24. Harvey CJ, O'Doherty MJ, Page CJ, Thomas SH, Nunan TO, Treacher DF (1995) Effect of a spacer on pulmonary aerosol deposition from a jet nebuliser during mechanical ventilation. Thorax 50:50-53
25. Thomas SH, O'Doherty MJ, Page CJ, Treacher DF, Nunan TO (1993) Delivery of ultrasonic nebulized aerosols to a lung model during mechanical ventilation. Am Rev Respir Dis 148:872-877
26. Diot P, Dequin PF, Rivoire B, Gagnadoux F, Faurisson F, Diot E, Boissinot E, Le Pape A, Palmer L, Lemarie E (2001) Aerosols and anti-infectious agents. J Aerosol Med 14:55-64
27. Dequin PF, Faurisson F, Lemarie E, Delatour F, Marchand S, Valat C, Boissinot E, de Gialluly C, Diot P (2001) Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis. Eur Respir J 18:316-322
28. Barclay ML, Kirkpatrick CM, Begg EJ (1999) Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 36:89-98
29. Rouby J, Goldstein I, Luin Q (2006) Inhaled antibiotic therapy. In: Tobin MJ (ed) Principles and practice of mechanical ventilation. McGraw-Hill, Columbus, pp 1311-1321
30. Dubus JC, Vecellio L, De Monte M, Fink JB, Grimbert D, Montharu J, Valat C, Behan N, Diot P (2005) Aerosol deposition in neonatal ventilation. Pediatr Res 58:10-14